CYP46A1 and neoplasm: Tumours that were negative for CYP46A1 (n=74) showed a mean patient survival of 117 months (95% CI 95-138), weakly stained tumours (n=173) had a mean survival of 128 months (95% CI 113-144) and moderately stained tumours (n=205) had a mean survival of 113 months (95% CI 100-126).